Nuwacell® hiPSC-mDAP（RC01008）, originally developed by Nuwacell Biotechnologies Co., Ltd. are high-purity (>90% Lmx1a+/Foxa2+/En1+) dopaminergic progenitors (mDAP) generated from human induced pluripotent stem cells (hiPSC). Nuwacell® hiPSC-mDAP can be expanded and passaged while maintaining the ability to differentiate into mature dopaminergic neurons (mDAN), which can be used in scientific research on neurodegenerative diseases, drug screening, and cell transplantation of Parkinson's disease models.
- ✔ hiPSC differentiated to mDAP on day 11.
- ✔ High-purity (>90% Lmx1a+/Foxa2+/En1+).
- ✔ Can Differentiated to mDAN.
- ✔ Cell recovery efficiency ≥80%.
(A-C) The morphology of hiPSC-mDAP cultured at day 1, 2, and 4 after cell recovery.
(D-E) The morphology of hiPSC-mDAP differentiated into mDNA at day 1, 9, and 30. Scale bar, 200μm.
Immunofluorescence staining of LMX1A, FOXA2, and EN1 for hiPSC-mDAP. Scale bar, 200 μm.
Immunofluorescence staining of TH and Nurr1 for differentiated mDAN. Scale bar, 200 μm.
A representative image of electrophysiological recording on individual mDAN at day 33 after cell recovery. Scale bar, 20 μm.
Representative traces of spontaneous action potentials at 2-10 Hz in the current-clamp mode.